Business
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to
About this update from Mineralys Therapeutics, Inc.
[{"type":"text","content":"RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced the appointment of Jeffrey A. Munsie as Chief Legal Officer. “Jeff brings deep life sciences experience across critical stages of growth, from preclinical through commercialization,” said Jon Congleton, Chief Executive Officer of Mineralys. “His strategic counsel, strong leadership, and proven track record will be instrumental in strengthening our legal and compliance capabilities.” Mr. Munsie joins Mineralys with nearly 25 years of comprehensive legal experience in the biopharma industry. Most recently, he served as Chief Legal Officer and Secretary at Orbital Therapeutics, where he oversaw IP strategy, contracting, compliance, and transactions. Earlier in his career, he held legal leadership roles at Concert Pharmaceuticals and Merrimack Pharmaceuticals, and he started his career in the corporate department at Wilmer Cutler Pickering Hale and Dorr in Boston. Mr. Munsie earned a J.D. from Harvard Law School and an A.B. from Dartmouth College. “I am thrilled to join Mineralys at such an important point in the company’s growth,” said Mr. Munsie. “I look forward to partnering with the team to advance lorundrostat and help bring it to as many appropriate patients as possible.” Additionally, on March 23, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 90,000 shares and an inducement restricted stock unit award covering 67,900 shares of Mineralys common stock to Mr. Munsie. The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option award will vest over a four-year period, with 25% of the total shares underlying the option vesting on the first anniversary of the award’s vesting commencement date, March 23, 2026, and 1/48th of the total shares underlying the option vesting following each one-month period thereafter, subject to continued service. The restricted stock unit award will vest over a four-year period, with 25% ...